Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Oak Ridge Investments LLC

Oak Ridge Investments LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,908 shares of the pharmaceutical company’s stock after buying an additional 81 shares during the quarter. Oak Ridge Investments LLC’s holdings in Vertex Pharmaceuticals were worth $768,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of VRTX. Benjamin F. Edwards & Company Inc. boosted its holdings in Vertex Pharmaceuticals by 18.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 5,892 shares of the pharmaceutical company’s stock valued at $2,761,000 after purchasing an additional 932 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 2.9% in the 2nd quarter. Pacer Advisors Inc. now owns 38,326 shares of the pharmaceutical company’s stock valued at $17,964,000 after buying an additional 1,085 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Vertex Pharmaceuticals by 6.5% in the second quarter. Thrivent Financial for Lutherans now owns 94,794 shares of the pharmaceutical company’s stock valued at $44,432,000 after buying an additional 5,827 shares in the last quarter. Summit Trail Advisors LLC grew its holdings in Vertex Pharmaceuticals by 14.8% during the second quarter. Summit Trail Advisors LLC now owns 2,881 shares of the pharmaceutical company’s stock worth $1,350,000 after acquiring an additional 372 shares during the period. Finally, Profund Advisors LLC raised its position in Vertex Pharmaceuticals by 12.1% in the second quarter. Profund Advisors LLC now owns 29,546 shares of the pharmaceutical company’s stock worth $13,849,000 after acquiring an additional 3,194 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ VRTX opened at $422.00 on Monday. The stock has a fifty day moving average price of $440.94 and a 200 day moving average price of $466.09. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a market cap of $108.68 billion, a P/E ratio of -212.06, a P/E/G ratio of 2.11 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the business posted $3.67 EPS. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of a number of recent analyst reports. Citigroup began coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $575.00 price target on the stock. BMO Capital Markets lowered their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. Truist Financial decreased their price target on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. StockNews.com downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Finally, Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.